                         SEQUENCE LISTING

<110>  Research Foundation for The State University of New York
 
<120>  PARTICLE BASED FORMULATIONS OF SARS-COV-2 RECEPTOR BINDING DOMAIN

<130>  011520.01638

<150>  63/085,734
<151>  2020-09-30

<160>  1     

<170>  PatentIn version 3.5

<210>  1
<211>  223
<212>  PRT
<213>  severe acute respiratory syndrome coronavirus 2

<400>  1

Arg Val Gln Pro Thr Glu Ser Ile Val Arg Phe Pro Asn Ile Thr Asn 
1               5                   10                  15      


Leu Cys Pro Phe Gly Glu Val Phe Asn Ala Thr Arg Phe Ala Ser Val 
            20                  25                  30          


Tyr Ala Trp Asn Arg Lys Arg Ile Ser Asn Cys Val Ala Asp Tyr Ser 
        35                  40                  45              


Val Leu Tyr Asn Ser Ala Ser Phe Ser Thr Phe Lys Cys Tyr Gly Val 
    50                  55                  60                  


Ser Pro Thr Lys Leu Asn Asp Leu Cys Phe Thr Asn Val Tyr Ala Asp 
65                  70                  75                  80  


Ser Phe Val Ile Arg Gly Asp Glu Val Arg Gln Ile Ala Pro Gly Gln 
                85                  90                  95      


Thr Gly Lys Ile Ala Asp Tyr Asn Tyr Lys Leu Pro Asp Asp Phe Thr 
            100                 105                 110         


Gly Cys Val Ile Ala Trp Asn Ser Asn Asn Leu Asp Ser Lys Val Gly 
        115                 120                 125             


Gly Asn Tyr Asn Tyr Leu Tyr Arg Leu Phe Arg Lys Ser Asn Leu Lys 
    130                 135                 140                 


Pro Phe Glu Arg Asp Ile Ser Thr Glu Ile Tyr Gln Ala Gly Ser Thr 
145                 150                 155                 160 


Pro Cys Asn Gly Val Glu Gly Phe Asn Cys Tyr Phe Pro Leu Gln Ser 
                165                 170                 175     


Tyr Gly Phe Gln Pro Thr Asn Gly Val Gly Tyr Gln Pro Tyr Arg Val 
            180                 185                 190         


Val Val Leu Ser Phe Glu Leu Leu His Ala Pro Ala Thr Val Cys Gly 
        195                 200                 205             


Pro Lys Lys Ser Thr Asn Leu Val Lys Asn Lys Cys Val Asn Phe 
    210                 215                 220             


